Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose dual therapy vs bismuth quadruple therapy for first-line Helicobacter pylori eradication in Hainan
ChiCTR2100046449Phase 4Recruiting
- Sponsor
- Haikou People's Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esomeprazole, amoxicillin, clarithromycin and colloidal bismuth pectin in Helicobacter pylori infection (2 arms), sponsored by Haikou People's Hospital. Primary endpoint: Eradication rate. Started Feb 2021; status: recruiting.
02
Drugs
esomeprazoleamoxicillinclarithromycincolloidal bismuth pectin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100046449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046449.